tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Boston Scientific price target raised to $120 from $115 at BofA

BofA analyst Travis Steed raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares. The company’s Q2 results continued to show strong upside with 17% organic growth, 28% watchman growth, and 94% EP growth, the analyst tells investors in a research note. The firm added that Q2 margins were also good excluding the transcatheter aortic valve replacement write-off, and noted that Boston Scientific is starting to see synergies between EP and Watchman post-concomitant expansion.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1